Study Title
Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT02429375)

Trial Description
The purpose of this study is to find out how safe and effective treatment with a new combination of drugs, mocetinostat and brentuximab vedotin, is in treating cancer. There will be 2 parts to this trial: a phase I part and a phase II part.

Brentuximab vedotin (Adcetris®; Seattle Genetics/Millennium: The Takeda Oncology Company) is approved by the U.S. Food and Drug Administration (FDA) to be given to patients with Hodgkin Lymphoma. Mocetinostat, an orally-bioavailable, spectrum-selective HDAC inhibitor (HDACs 1, 2, 3 and 11), is an experimental drug being developed by Mirati Therapeutics (San Diego, CA), that has been given to patients with Hodgkin lymphoma in another clinical trial. When given alone, mocetinostat caused lymphoma to shrink in about 1 out of 4 patients with Hodgkin lymphoma. This is the first study that will give mocetinostat and brentuximab vedotin together.

This trial is sponsored by Memorial Sloan Kettering Hospital. [1]

Study Data

  • Condition: Hodgkin Lymphoma
  • Interventions:
  • Phase: I & II
  • Estimated Enrollment: 44
  • Start: April 2015
  • Estimated Primary Completion: April 2018
  • Last verified: April 2015

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: July 17, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.